Optically active hydantoin derivatives, their synthesis, pharmaceutical formulations containing them, and intermediates
申请人:THE WELLCOME FOUNDATION LIMITED
公开号:EP0019223A1
公开(公告)日:1980-11-26
Compounds of formula (I)
having only two optically active centres, may exist as four isomers, each of which may be prepared by resolving a racemic amino-diester intermediate in the preparation thereof. The racemic amino-diester is selectively hydrolysed to the corresponding mono-ester which is acylated and subsequently selectively deacylated to produce the resolved mono-ester.
Isomers of compounds of formula (I) having a particular configuration are biologically more active than the corresponding isomers having other configurations and are useful in medicine, either as the raw compound or in a pharmaceutical formulation, for example in inhibiting platelet aggregation.
式 (I) 化合物
只有两个光学活性中心,可以存在四种异构体,每种异构体都可以通过分解制备过程中的外消旋氨基二酯中间体来制备。外消旋氨基二酯被选择性水解为相应的单酯,单酯被酰化,随后选择性脱酰化,生成已解析的单酯。
具有特定构型的式 (I) 化合物异构体比具有其他构型的相应异构体具有更高的生物活性,可作为原料化合物或药物制剂用于医药领域,例如抑制血小板聚集。